We have detected that Javascript is not enabled in your browser. The dynamic nature of our site means that Javascript must be enabled to function properly. Please read our terms and conditions for more information.

Next up

Non-Small Cell Lung Cancer Treatment Regimens

Description

Understand U.S., Western Europe, and Japanese markets for first/second/third line treatment for NSCLC with regards to Stage (I-IV) and histology/biomarkers (squamous, non-squamous, EGFR mutant, and ALK mutant).

Mind Map by Shane Naki, updated more than 1 year ago

	Created by Shane Naki almost 10 years ago

14

0

Resource summary

Non-Small Cell Lung Cancer Treatment Regimens

Systemic Regimens by Country
1. United States (2015)
  1. Carboplatin + Alimta + Avastin
  2. Carboplatin + paclitaxel
  3. Xalkori
  4. Tarceva
  5. United States
    1. docetaxel
    2. docetaxel
    3. Gilotrif
    4. Zykdaia
    5. United States
      1. Opdivo
      2. Tarceva
      3. Opdivo
      4. Opdivo
2. Western Europe (2015)
  1. cisplatin + gemcitibine
  2. Cisplatin + Alimta
  3. Tarceva
  4. Xalkori
  5. Western Europe
    1. docetaxel
    2. docetaxel
    3. cisplatin + Alimta
    4. Xalkori
    5. Western Europe
      1. Vinorelbine
      2. Vinorelbine
      3. Vinorelbine
      4. vinorelbine
3. Japan (2014)
Treatment Line
1. 1
  1. Squamous
    1. Non-Squamous
      1. EGFR mutant
        ALK Mutant
  2. 2
    1. 3
      1. Squamous
        Non-Squamous
        EGFR Mutant
        ALK Mutant
    2. Squamous
      1. Non-Squamous
        EGFR Mutant
        ALK Mutant

Show full summary Hide full summary

Want to create your own Mind Maps for free with GoConqr? Learn more.

Similar

QuintilesIMS Institute 2016: Outlook for Global Medicine through 2021

Shane Naki